San Antonio Breast Cancer Symposium (SABCS)

Hypofractionation and tailored radiotherapy can help avoid radiation-associated toxicities in women with early breast cancer.

Despite limited data, neoadjuvant endocrine therapy appears to improve surgical outcomes and “to be as effective as chemotherapy.”

Reducing dietary fat intake appears to improve survival rates among women with certain types of breast cancer.

Adding ovarian function suppression (OFS) is associated with several patient-reported endocrine symptoms and impacts sexual functioning.

Adding ovarian function suppression (OFS) to adjuvant postsurgical tamoxifen therapy can reduce breast cancer recurrence.

TP53 mutation, but not PIK3CA status, predicts treatment response in HER2-positive breast cancer.

PIK3CA mutation status and PAM50 tumor subtype do not predict poor trastuzumab response in the adjuvant setting.

Capecitabine monotherapy does not improve outcomes in elderly patients with moderate- or high-risk early breast cancer.